This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Miltenyi Biotec, Gmbh. Active years: 2010-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010-2016
Title: Biography of Marco Frentsch
Introduction: Marco Frentsch is an accomplished inventor based in Berlin, Germany. He has made significant contributions to the field of immunology, particularly in the identification and separation of T-cells. With a total of three patents to his name, Frentsch is recognized for his innovative approaches in cellular research.
Latest Patents: His latest patents include a method for the identification and separation of non-regulatory T-cells from a mixture of regulatory T-cells. This invention utilizes the CD154 molecule to deplete CD154+ T-cells and includes additional positive selection of regulatory T-cells using specific markers. Another notable patent involves the use of the 4-1BB receptor for identifying and separating activated regulatory Th cells, which is crucial for advancing therapeutic strategies in immunology.
Career Highlights: Marco Frentsch is currently employed at Miltenyi Biotec GmbH, a leading company in the field of biotechnology. His work focuses on developing innovative solutions for cell separation and analysis, contributing to advancements in medical research and treatment.
Collaborations: Throughout his career, Frentsch has collaborated with esteemed colleagues such as Andreas Thiel and Anne Schönbrunn. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking technologies in immunology.
Conclusion: Marco Frentsch's contributions to the field of immunology through
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile